Loading...
Market
Will Biomarin's Voxzogo lose more than 20% market share by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market research reports or Biomarin's financial reports
Story
Ascendis Pharma's TransCon CNP Achieves Primary Objective in ApproaCH Trial, Stock Surges 19.9%
Sep 16, 2024, 12:02 PM
Ascendis Pharma (ASND) announced that its pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) achieved its primary objective, demonstrating a superior annual growth velocity (AGV) compared to placebo. The trial showed a least squares mean treatment difference of 1.49 cm/year at Week 52, with children aged 5-11 years showing a change from baseline AGV superior to placebo with a least squares mean treatment difference of 1.78 cm/year at Week 52. Following the announcement, Ascendis Pharma's stock surged by 19.9% in pre-market trading. This development poses a competitive challenge to Biomarin's Voxzogo, which was previously considered superior. Ascendis Pharma's stock was up +17% in pre-market trading, while Biomarin's stock dropped by 15%. The trial was double-blind and placebo-controlled.
View original story
Similar markets
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
